ArticleImmunity, inflammation and disease2026
Baicalin as a Regulator of Peroxisome Proliferator-Activated Receptor Gamma: Alleviating Sepsis-Induced Liver Injury by Inhibiting the Cluster of Differentiation 14/Nuclear Factor Kappa B Signaling Pathway.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSepsis frequently results in multiple organ failure, with the liver particularly susceptible to sepsis-induced damage. The flavonoid baicalin (BA), derived from Scutellaria baicalensis, presents anti-inflammatory properties, yet its effects on liver injury in sepsis through the Cluster of Differentiation 14 (CD14)/Nuclear Factor kappa B (NF-κB) pathway remain underexplored.
methodsAlpha Mouse Liver 12 (AML12) cells were intervened with different concentrations of BA and subsequently challenged with lipopolysaccharide (LPS) to induce inflammation. Cell viability, apoptosis, inflammatory cytokine production, and signaling pathway activation were tested by Cell Counting Kit 8 (CCK8), flow cytometry, quantitative real-time PCR (qRT-PCR) and western blotting, respectively. And immunofluorescence was employed to visualize nuclear ectopic location of NF-κB in cells. Additionally, the impact of peroxisome proliferator-activated receptor gamma (PPARγ) silencing for BA's function was explored using small interfering RNA (siRNA) techniques.
resultsBA significantly improved viability and decreased apoptosis in LPS-treated cells. It also downregulated tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β) and IL-6, upregulated PPARγ, and diminished CD14 and phosphorylated inhibitor of kappa B alpha (p-IKBα)/IKBα levels. Silencing PPARγ reversed the protective effects of BA, underscoring the importance of PPARγ in BA's mechanism of action.
conclusionBA alleviates sepsis-induced liver injury through activating PPARγ and inhibiting CD14/NF-κB pathway, highlighting its potential as a new approach to treatment sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.